ABSTRACT:
Background: Breast cancer hasa high incidence and death rates, and cyclooxygenase-2 (COX-2) is a promising enzyme in as prognostic and monitoring factor. Objective: Determination the relation between serum COX-2 concentrationand the stage and grade of breast cancer as a prognostic parameters. Methodology: This study is prospective, cross sectional type, include 30 women with breast cancer, met the study criteria. the serum COX-2 value was calibrated. The data was entered into the computer's SPSS program. Results: Patients were 48.33 ± 7.84 years old, and 70% of tumors in the first and second stages, while more than half of the tumors were in the third grade. The mean of serum COX-2 values was 372.31 ± 173.42 U/L.Serum COX-2 level was positively and significantly correlated with tumor stage and grade(P <0.01). Conclusion: Serum COX-2 values correlate with the stage and grade in breast cancers.
Cite this article:
Fatima Moselmani , Jumana Al- Saleh. Relation between Serum cyclo oxygenase-2 values and Tumor characteristics in breast cancer patients. Research J. Pharm. and Tech 2020; 13(9):4320-4322. doi: 10.5958/0974-360X.2020.00763.5
Cite(Electronic):
Fatima Moselmani , Jumana Al- Saleh. Relation between Serum cyclo oxygenase-2 values and Tumor characteristics in breast cancer patients. Research J. Pharm. and Tech 2020; 13(9):4320-4322. doi: 10.5958/0974-360X.2020.00763.5 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-9-51
REFERENCES:
1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64: 9-29.
2. Howe LR, Subbaramaiah K, Brown AMC, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer 2001,8:97–114.
3. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. British Journal of Cancer 2006,94:346–350.
4. Xu F, Li M, Zhang C, et al. Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis. Oncotarget, 2017, 8(4): 6003-6012
5. Shalaby MA, Nounou HA, Ms A, et al. Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population. Asian Pac J Cancer Prev 2014, 15: 4989-4994.
6. Peng WJ, Wang BX, He Q, et al. Association of COX-2 8473T>C gene polymorphism with lung cancer risk. Asian Pac J Cancer Prev 2011,12:3157-8.
7. He WT, Liu T, Tang XF, et al. The COX-2 -765 G>C polymorphism is associated with increased risk of gastric carcinogenesis in the Chinese Hui ethnic population. Asian Pac J Cancer Prev 2014, 15, 4067-70.
8. Xu YS, Zhao B, Long CY, et al. Cyclooxygenase-2 promoter 765C increase of digestive tract cancer risk in the Chinese population: a meta-analysis. Asian Pac J Cancer Prev 2014, 15, 4563-6.
9. Zhao F, Zhu H, Huang M, et al. The 765G>C polymorphism in the cyclooxygenase-2 gene and gastric cancer risk: an update by meta-analysis. Asian Pac J Cancer Prev 2014, 15, 2863-8.
10. Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev. 2011; 30: 449–463.
11. Lim SC. Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. Oncol Rep. 2003; 10:1241–1249.
12. Yoshinaka R, Shibata MA, Morimoto J, et al. COX-2 inhibitor celecoxib suppresses tumorgrowth and lung metastasis of a murine mammary cancer. Anticancer Res. 2006; 26(6B):4245–4254.
13. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res, 2003,63: 6096-101.
14. Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 2004, 4: 428-33.
15. Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol 2014; 5: 677-692